Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Autor: Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH, Thomas, Eva S, Gomez, Henry L, Li, Rubi K

Publikováno v: Journal of Clinical Oncology; 11/20/2007, Vol. 25 Issue 33, p5210-5217, 8p

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.

Autor: Blum JL; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, Texas., Laird AD; Pfizer Inc., La Jolla, California., Litton JK; The University of Texas MD Anderson Cancer Center, Houston, Texas., Rugo HS; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Ettl J; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Hurvitz SA; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, California., Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain., Roché HH; Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France., Lee KH; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea., Goodwin A; Concord Repatriation General Hospital, Sydney, Australia., Chen Y; Pfizer Inc., La Jolla, California., Lanzalone S; Pfizer Inc., Milan, Italy., Chelliserry J; Pfizer Inc., La Jolla, California., Czibere A; Pfizer Inc., Cambridge, Massachusetts., Hopkins JF; Foundation Medicine Inc., Cambridge, Massachusetts., Albacker LA; Foundation Medicine Inc., Cambridge, Massachusetts., Mina LA; Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Gilbert, Arizona.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 01; Vol. 28 (7), pp. 1383-1390.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.

Autor: Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030-4009, USA. ghortoba@mdanderson.com, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2010 Jul; Vol. 122 (2), pp. 409-18. Date of Electronic Publication: 2010 May 08.